Botanix Pharmaceuticals (ASX:BOT) ROCE % : -31.96% (As of Dec. 2023)

View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Botanix Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was -31.96%.

Botanix Pharmaceuticals ROCE % Historical Data

The historical data trend for Botanix Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals ROCE % Chart

Botanix Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-201.53

-135.90

-14.62

-90.38

-58.34

Botanix Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-73.47	-117.75	-72.53	-45.83	-31.96

Botanix Pharmaceuticals ROCE % Calculation

Botanix Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-9.072	/	( ( (14.037 - 5.886)	+	(24.836 - 1.885) )	/ 2 )
	=	-9.072	/	( (8.151	+	22.951)	/ 2 )
	=	-9.072	/	15.551
	=	-58.34 %

Botanix Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-10.922	/	( ( (24.836 - 1.885)	+	(47.681 - 2.291) )	/ 2 )
	=	-10.922	/	( ( 22.951	+	45.39 )	/ 2 )
	=	-10.922	/	34.1705
	=	-31.96 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Botanix Pharmaceuticals (ASX:BOT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Botanix Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Botanix Pharmaceuticals (ASX:BOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BXPHF:USA

Address

661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007

Website

https://www.botanixpharma.com

Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines